The decision this page changes. Is a consumer wearable activity tracker (Fitbit, Jawbone, and kin) a worthwhile adherence / behaviour-change lever — a device that gets a person to move more and keeps them moving? This is a Layer-3 adherence-is-part-of-the-effect / structural-leverage question, not a new dose-response fact about activity itself: the tracker does not change what a dose of activity does (that lives at Physical Activity Dose and Mortality) — it is a candidate tool for reaching and sustaining the dose.
Verdict — a small, real short-term boost to activity; durability unproven; effect on a surrogate
A consumer tracker moves physical-activity participation up by a small-to-moderate amount over the short term, but on low-to-very-low certainty, and the outcome measured is the activity itself (a surrogate), not a patient-important endpoint. The one thing the device is pitched to solve — the well-known decay of activity-intervention effects over time — is exactly what this evidence does not establish.
Brickwood et al. 2019 (SR + random-effects MA, 28 RCTs / 3646 participants across 9 countries, apparently-healthy through chronic-condition adults; trackers used either as the whole intervention [wearable-based] or inside a broader programme [multifaceted]) vs interventions without tracker feedback. All SMDs are standardized mean differences (pooled SD units), not clinical units; the raw-unit conversions below come from the source’s own pooled-SD back-conversion and are the fragile object — the SMD and its interval are the robust one. (Brickwood et al., 2019)
The four pooled effects (Results-body figures; carry CI + I^2 + GRADE)
- Daily step count — the cleanest signal. «There was a significant increase in step count following the intervention versus control comparator (SMD 0.23; 95% CI 0.15 to 0.32; P<.001; Figure 3) across all studies in the meta-analysis, representing an approximate increase of 627 steps (95% CI 417 to 862 steps) per day. Heterogeneity was low [88] and nonsignificant (I2=3%; P=.42).» GRADE low (downgraded twice: risk of bias, indirectness). Step data were objectively measured. The ~627 steps/day (CI 417-862) is the most interpretable anchor on the page. (Brickwood et al., 2019)
- Moderate + vigorous PA (MVPA). «significant increase in minutes per day spent in MVPA … (SMD 0.28; 95% CI 0.14 to 0.41; P<.001; Figure 4)», I^2=46% (moderate, significant). GRADE very low (downgraded 3x: bias, inconsistency, indirectness). The source’s raw-unit conversion — «an approximate increase of 75 min (95% CI 42 to 109 min) per day of MVPA» — is implausibly large and should be read as a pooled-SD-conversion artifact across heterogeneous, partly self-reported measures, not a literal +75 min/day; the SMD 0.28 is the object to trust. (Brickwood et al., 2019)
- Energy expenditure. «significant increase in energy expenditure … (SMD 0.32; 95%CI 0.05 to 0.58; P=.02; Figure 5)», I^2=33% (low, ns); «approximate increase of 300 kcal (95% CI 32 to 579) in energy expenditure per week». GRADE low. Measured by self-report questionnaire (Paffenbarger / IPAQ) in all five studies — the weakest-measured outcome. (Brickwood et al., 2019)
- Sedentary behaviour — NOT significant. «nonsignificant decrease in sedentary behavior … (SMD −0.21; 95% CI -0.46 to 0.03; P=.09; Figure 6)», I^2=60% (moderate, significant); «approximately 37 min (95% CI −81 to 5 min) less spent in sedentary behavior». GRADE very low. The interval crosses zero: a tracker aimed at adding activity does not reliably cut sitting — and the source notes interventions that specifically target sedentary behaviour are more effective than PA-promotion that hopes to reduce sitting as a by-product -> Sedentary Behaviour and Chronic Disease Risk. (Brickwood et al., 2019)
The abstract reports marginally different pooled SMDs (step 0.24 [0.16-0.33]; MVPA 0.27 [0.15-0.39]; EE 0.28 [0.03-0.54]; sedentary −0.20 [−0.43 to 0.03]) — rounding/recomputation differences from the Results-body values quoted above; the direction, significance pattern, and certainty are identical. (inferred from Brickwood et al., 2019)
Durability — the crux, and it is NOT established
The device is sold on solving activity decay, and the source concedes the problem while showing its own evidence cannot demonstrate the fix.
- The measured effects are SHORT-TERM. «Although findings were not significant in all studies, short-term interventions utilizing a consumer-based wearable activity tracker generally resulted in increased physical activity participation.» The pooled estimate is a short-horizon quantity. (Brickwood et al., 2019)
- Longer trials showed WORSE adherence. «Actual wear time of the activity tracker varied, ranging from over 90% wear time [21,22] to all participants ceasing to wear the device by the end of the intervention [32] … The 2 studies that were 12 months or longer [32,37] reported lower adherence rates compared with shorter duration studies. Issues with long-term adherence to lifestyle and behavioral change interventions are well recognized.» So the only long-horizon data point runs the wrong way for the durability claim. (Brickwood et al., 2019)
- The novelty-factor caveat. «Given the potential novelty factor associated with the use of consumer-based wearable activity trackers, further investigation into their long-term usage and effectiveness would be useful.» The authors themselves flag that the short-term boost may be a wear-it-because-it’s-new effect. (Brickwood et al., 2019)
- The authors’ own framing is a TOOL for clinicians, not a self-sufficient durable lever. «The effects of physical activity interventions are generally short term, with ongoing contact from health professionals increasing long-term adherence to physical activity participation. Therefore, consumer-based wearable activity trackers have the potential to be included as an effective tool to assist health professionals to provide ongoing monitoring and support to patients with minimal resource expenditure.» The structural-leverage claim is conditional on ongoing human contact, not demonstrated for the device alone over the long run. (Brickwood et al., 2019)
What the effect is made of, and how to weight it
- Standalone vs bundled. «even without supporting behavior change techniques, the use of a consumer-based wearable activity tracker could be effective in increasing physical activity participation» — so the device carries some effect on its own. But «intervention groups that were multifaceted in nature appeared to have a greater effect on physical activity participation … than those that included just the use of a consumer-based wearable activity tracker» (steps: wearable-only SMD 0.20 [0.08-0.33] vs multifaceted 0.26 [0.12-0.41]). The tracker is a component that adds most when bundled with counselling, education, or financial incentives — consistent with the ongoing-contact durability point. (Brickwood et al., 2019)
- Risk of bias — one unavoidable flaw. «All studies were assessed as high risk of bias for performance bias because of the nature of the intervention and control conditions making blinding impossible.» A tracker cannot be blinded — a behaviour intervention people know they are receiving — so the whole evidence base carries irreducible performance bias, and the Hawthorne/expectancy component cannot be separated from the device effect. Otherwise studies were generally low risk. This is the same blinding-is-impossible problem the whole PA-intervention literature carries. (Brickwood et al., 2019)
- The device’s own step counts over-read. «a recent review into the use of Fitbit activity trackers suggests that steps are overestimated in free-living conditions» — a measurement caveat on trackers as measuring instruments (distinct from their behaviour-change role; the trial outcomes were mostly on independent accelerometers). (Brickwood et al., 2019)
- Outcome is a surrogate. Every effect here is on activity participation, not on mortality, cardiometabolic, or function endpoints. The transmission from “+627 steps/day” to a patient-important outcome runs through Physical Activity Dose and Mortality (where ~+600-700 steps/day near the low-active end is a meaningful mortality-relevant increment) — but that transmission is an inference, not measured in this MA -> Surrogate Outcomes.
Where it sits in the Layer-1 ranking
For a reasonably-healthy, already-somewhat-active person, this is a small, low-certainty lever: it does not change the activity dose-response, only the odds of reaching/holding a dose, and only the short-term odds are shown. It ranks as an adherence aid, not a big rock — most useful for a near-inactive person (large baseline gap, where +627 steps/day is worth most) and most credible when paired with human contact rather than as a stand-alone gadget. The device is not a substitute for the activity; it is a candidate scaffold for doing it. -> Layer 1 - Ranking Interventions for a Stratum
Gaps
- Long-term (>12 month) durability of the device effect is unestablished — the two long trials showed lower adherence, and no pooled long-horizon estimate exists. No SR/MA of long-follow-up wearable-tracker RCTs is held or known to exist; kept as an open gap, not a tracked await (nothing specific to acquire). (Brickwood et al., 2019)
- No patient-important endpoint — the MA cannot say whether the activity boost translates into
mortality, cardiometabolic, or function benefit; that is
G (needs aggregation)across a different evidence base. - Self-monitoring consumer DEVICES may form a future cross-cutting concept. A wearable activity tracker and a CGM answer the same question class — does a consumer self-monitoring wearable that surfaces a real-time personal signal change behaviour and, through it, a health outcome? Both land the same shape of answer: a modest effect on a surrogate (steps / HbA1c), high heterogeneity, low certainty, and unproven durability. Flagged as a candidate concept, not built — it needs a second device class beyond these two before a cross-source synthesis is warranted. (inferred from Brickwood et al., 2019)